Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Bought by Atticus Wealth Management LLC

Atticus Wealth Management LLC increased its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 56.3% in the 4th quarter, Holdings Channel reports. The firm owned 47,762 shares of the company’s stock after buying an additional 17,199 shares during the period. Atticus Wealth Management LLC’s holdings in Tenaya Therapeutics were worth $68,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Synovus Financial Corp purchased a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth about $28,000. SG Americas Securities LLC purchased a new stake in shares of Tenaya Therapeutics in the third quarter valued at about $49,000. The Manufacturers Life Insurance Company grew its position in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Tenaya Therapeutics in the second quarter valued at approximately $74,000. Finally, XTX Topco Ltd increased its stake in shares of Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TNYA shares. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Tuesday, January 14th. Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital reissued a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $1.21 on Monday. Tenaya Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $7.01. The stock’s 50-day moving average is $2.12 and its two-hundred day moving average is $2.37.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. As a group, equities analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.